Abbott Laboratories Cash Flow Statement
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories free cash flow
In fiscal 2025, Abbott Laboratories generated $9.57 billion of operating cash flow and spent $2.17 billion on capital expenditures. That left free cash flow of $7.39 billion, a free-cash-flow margin of 16.7% of revenue. Free cash flow was up 16.4% from the prior year's $6.35 billion.
Abbott Laboratories returned $5.01 billion to shareholders: $4.12 billion in dividends and $893.0 million in share repurchases, equal to 68% of free cash flow. Free cash flow covered dividend payments 1.8 times.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B |
| Net Income growth (YoY) | -51.32% | +134.18% | -17.45% | -1.95% | +57.31% | +21.91% | +55.70% | +396.44% | -65.93% | -68.35% |
| Depreciation & Amortization | 1.43B | 1.34B | 1.28B | 1.25B | 1.49B | 1.20B | 1.08B | 1.10B | 1.05B | 803.00M |
| Stock-Based Compensation | 664.00M | 673.00M | 644.00M | 685.00M | 640.00M | 546.00M | 519.00M | 477.00M | 406.00M | 310.00M |
| Change in Working Capital | -798.00M | -1.19B | -1.89B | -1.14B | 137.00M | -278.00M | -786.00M | 66.00M | 766.00M | -814.00M |
| Operating Cash Flow | 9.57B | 8.56B | 7.26B | 9.58B | 10.53B | 7.90B | 6.14B | 6.30B | 5.57B | 3.20B |
| Capital Expenditures | -2.17B | -2.21B | -2.20B | -1.78B | -1.89B | -2.18B | -1.64B | -1.39B | -1.14B | -1.12B |
| Investing Cash Flow | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B | -1.81B | -1.36B | -9.62B | -248.00M |
| Dividends Paid | -4.12B | -3.84B | -3.56B | -3.31B | -3.20B | -2.56B | -2.27B | -1.97B | -1.85B | -1.54B |
| Share Repurchases | -893.00M | -1.29B | -1.23B | -3.79B | -2.30B | -403.00M | -718.00M | -238.00M | -117.00M | -522.00M |
| Debt Issued | — | — | — | — | 4.00M | 1.28B | 1.84B | 4.01B | 6.74B | 14.93B |
| Debt Repaid | — | — | — | — | -48.00M | -1.33B | -3.44B | -12.43B | -8.65B | -12.00M |
| Financing Cash Flow | -6.31B | -5.40B | -7.09B | -7.64B | -5.49B | -2.78B | -4.29B | -10.39B | -5.28B | 11.15B |
| Net Change in Cash | 906.00M | 720.00M | -2.99B | 83.00M | 2.96B | 2.98B | 16.00M | -5.56B | -9.21B | 13.62B |
| Free Cash Flow | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B | 4.50B | 4.91B | 4.43B | 2.08B |
This table shows 10 annual periods of Abbott Laboratories's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a cash flow statement?